Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
October 19, 2015 at 08:00 AM EDT
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced the initiation of a randomized phase 2 clinical trial of Rituxan (rituximab) and ...